WO2019175364A1 - Composition de traitement - Google Patents

Composition de traitement Download PDF

Info

Publication number
WO2019175364A1
WO2019175364A1 PCT/EP2019/056511 EP2019056511W WO2019175364A1 WO 2019175364 A1 WO2019175364 A1 WO 2019175364A1 EP 2019056511 W EP2019056511 W EP 2019056511W WO 2019175364 A1 WO2019175364 A1 WO 2019175364A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
hair
skin
fucose
subject
Prior art date
Application number
PCT/EP2019/056511
Other languages
English (en)
Inventor
Helena MCMAHON
Aleksandra AUGUSTYNIAK
Original Assignee
Institute of Technology, Tralee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB1804226.7A external-priority patent/GB2572322A/en
Priority claimed from GBGB1804251.5A external-priority patent/GB201804251D0/en
Application filed by Institute of Technology, Tralee filed Critical Institute of Technology, Tralee
Publication of WO2019175364A1 publication Critical patent/WO2019175364A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Definitions

  • the present invention relates to a treatment composition, especially hair treatment compositions and skin treatment compositions. Also contemplated are methods of treating hair with a composition to promote hair growth, prevent hair loss, and improve the condition, composition or quality of hair, and methods of treating skin with a composition to improve the condition of skin, inhibit skin aging, and rejuvenate the skin.
  • the hair follicle is considered to be a mini-organ with a plethora of different cell types which co-ordinate the hair growth cycle through a complex cascade of signalling pathways.
  • Crucial element in the hair follicles for maintaining normal hair growth cycle are mesenchymal derived Dermal Papilla Cells (DPC).
  • DPC mesenchymal derived Dermal Papilla Cells
  • the task performed by these cells during the hair growth cycle makes them an excellent model for in vitro evaluation of molecules with hair growth promoting properties.
  • Manipulating the course of hair growth cycle comprises the basic therapeutic strategy for all type of hair loss. Hair growth promoting products should induce or prolong the anagen phase, induce anagen in telogen phase follicles, inhibit catagen as well as inhibit of exogen (shedding phase of hair cycle).
  • Targeting of the anagen phase is a favoured strategy as it enables targeting of the induction of new hair follicle formation and / or prolonging the duration and rate of hair growth.
  • the key biomarkers of the anagen phase of the hair cell cycle is an increase in Dermal Papilla Cells proliferation, an increase in alkaline phosphatase activity levels and expression of growth factors such as insulin growth factor.
  • Currently used therapeutic agents, Minoxidil and Finasteride are not effective treatment tool in all cases of hair loss. Furthermore, their effectiveness is less when used alone and they can cause unwanted side effects.
  • JP2006016313 discloses sulphated poly fucose and sea cucumber chondroitin sulphate composition for promoting cell growth promoting hair growth.
  • EP0211610 discloses use of chondroitin disaccharide for topical application to the hair.
  • EP0354595 discloses the use of chondroitin disaccharide for topical application to the hair.
  • JP2005/178493 discloses that salts, and tri-sulphuric acid ester, of chondroitin disaccharide are elastin promoters useful in promoting reduction in elastin levels, and suggests that chondroitin disaccharide can be used for delaying skin aging.
  • US2011/028400 discloses the use of chondroitin disaccharide for the repair of connective tissue.
  • the present invention provides a composition, which may be a topical composition or oral composition, that is useful in treating hair or skin in a subject and that contains effective amounts of chondroitin disaccharide and L-fucose.
  • a composition which may be a topical composition or oral composition, that is useful in treating hair or skin in a subject and that contains effective amounts of chondroitin disaccharide and L-fucose.
  • the combination of these components has been found to have a synergistic effect in increasing the alkaline phosphatase activity levels in primary human follicle dermal papilla cells (a marker of growth / anagen phase of the hair cycle), compared with treatment with the individual components (Example 4 and Table 2).
  • a composition comprising L-fucose and/or chondroitin disaccharide.
  • the composition comprises an effective amount of L-fucose and an effective amount of chondroitin disaccharide.
  • composition is formulated for topical administration (topical composition).
  • the composition is formulated for oral delivery (oral composition).
  • the composition comprises 5.0 to 0.005 % L-fucose (w/v) and 1.0 to 0.00001 % chondroitin disaccharide (w/v). In one embodiment, the composition comprises 1.0 to 0.005 % L-fucose (w/v) and 0.1 to 0.00001 % chondroitin disaccharide (w/v).
  • the composition comprises 0.5 to 0.005 % L-fucose (w/v).
  • the composition comprises 0.1 to 0.01 % L-fucose (w/v).
  • the composition comprises 0.5 to 0.00005 % chondroitin disaccharide (w/v).
  • the composition comprises 0.05 to 0.00005 % chondroitin disaccharide (w/v).
  • the composition comprises 0.01 to 0.0001 % chondroitin disaccharide (w/v).
  • the composition comprises 0.5 to 0.005 % L-fucose (w/v) and 0.05 to 0.00005 % chondroitin disaccharide (w/v).
  • the composition comprises 0.2 to 0.005 % L-fucose (w/v) and 0.05 to 0.00005 % chondroitin disaccharide (w/v). In one embodiment, the composition comprises about 0.1 to 0.01 % L-fucose (w/v) and about 0.01 to 0.0001 % chondroitin disaccharide (w/v).
  • the topical composition is selected from a gel, cream, ointment or lotion. In one embodiment, the topical composition is selected from a shampoo, conditioner or shower/body gel.
  • the composition is formulated for oral delivery, and is typically provided in the form of unit dose product, for example a tablet, nutraceutical tablet, capsule, sachet, beverage, or food product.
  • the L-fucose is derived from a marine algae. In one embodiment, the L- fucose is derived from a seaweed. In one embodiment, the seaweed is selected from the range of brown Phaeophyceae, alage and certain sea animals such as sea cucumbers and sea urchins.
  • L-Fucose may also be produced via biotechnological processes or via extraction from other plant, fruit, vegetable and fungi species such as mushrooms, tomatoes and various seeds.
  • the chondroitin disaccharide is derived from a marine, animal or Avians or Invertebrate species. In one embodiment, the chondroitin disaccharide is derived from a bone, shell, cartilage, skin, intestine or other GAG and proteoglycan rich materials
  • the chondroitin disaccharide is chondroitin disaccharide salt. In one embodiment, the chondroitin disaccharide salt is chondroitin disaccharide Adi-4S sodium salt
  • the topical composition comprises one or more cosmetically acceptable excipients.
  • the oral composition comprises one or more nutritional or nutraceutical components.
  • the invention provides a method of treating a mammal to improve the growth or condition, or inhibit loss, of the mammals’ hair, the method comprising a step of administration of an effective amount of the composition of the invention to the mammal.
  • the composition is a topical composition and the method comprises topical administration of the composition it is generally applied to the skin where the hair grows, usually the scalp, but it may also be applied to the face, neck, chest, back, legs or arms.
  • the topical composition is topically applied to a scalp of the mammal.
  • the topical composition is applied every 1-10 days, for example once every 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 days.
  • the composition is not washed off once applied for a period of at least 1, 2, 4, 8, 12, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96 or 108 hours.
  • the invention also relates to a composition of the invention for use in promoting growth of epithelial tissue.
  • the invention also relates to a composition of the invention for use in promoting growth of skin.
  • the tissue has a normal pathology (for example ageing skin).
  • the cell, tissue or skin has abnormal pathology (for example tissue damaged due to trauma or disease).
  • the growth promoting uses may be in-vivo or in-vitro uses.
  • the growth promoting uses may involve administration to mammal externally (i.e. to the skin) or internally (i.e. oral or IV administration).
  • the invention also relates to a composition of the invention for use in slowing or inhibiting ageing of human skin.
  • the invention also relates to a composition of the invention for use in rejuvenating human skin.
  • the invention also relates to a composition of the invention for use in treating human skin to improve the appearance or condition of the skin.
  • the composition of the invention is administered topically to the skin. Administration may be by means of a plaster, bandage or patch or a formulation suitable for topical application. The composition may also be administered orally.
  • the invention also relates to a composition of the invention for use in treatment of a wound in a mammal, typically to promote or accelerate re-epithelialisation of the wound.
  • the invention also relates to a composition of the invention for use in treatment or prevention of a disorder of the skin, especially an inflammatory disorder of the skin, characterised by damaged dermal or epithelial tissue.
  • the disease or condition is selected from a microbial skin infection, dermatitis (for example atopic dermatitis or contact dermatitis), acne vulgaris, eczema, and psoriasis.
  • the invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a composition of the invention in combination with a pharmaceutically acceptable carrier.
  • the invention also relates to a composition of the invention for use in treatment or prevention of an inflammatory disorder in a mammal.
  • the composition is formulated for oral administration, and is orally administered to the mammal.
  • the oral composition is administered daily.
  • the oral composition is administered as a regimen over a 30 day period, which can involve a range of days between administrations from 1 - 30 or any combination thereof
  • the oral composition is administered once or several times a day, or every 2-30 days, for a period of time until the composition is effective.
  • Figure 1 Effect of simultaneous treatment with L-fucose and Chondroitin disaccharide D- di 4S sodium salt on proliferation in Dermal Papilla Cells.
  • FIG. 1 Alkaline Phosphatase Activity Levels in Primary Dermal Papilla Cells following treatment with L-Fucose.
  • HDFC cells were treated with L-Fucose at 0.1 - 0.001 w/v for up to 168 hours with alkaline phosphatase activity levels evaluated at 72, 120 & 168 hours post treatment. The largest increase was observed at 168 hrs post treatment with 0.001% w/v L- Fucose.
  • Figure 3 Effect of Chondroitin disaccharide Adi-4S sodium salt on Alkaline Phosphatase expression in primary Human Follicle Dermal Papilla Cells.
  • HDFC cells were treated with Chondroitin Disaccharide at 0.1 - 0.0001 w/v for up to 168 hour with alkaline phosphatase activity levels evaluated at 72, 120 & 168 hours post treatment. The largest increase was observed with a 128% increase at 168 hrs post treatment with 0.01% w/v Chondroitin Disaccharide.
  • FIG. 4 Alkaline Phosphatase Activity Fevels in primary dermal papilla cells in response to F-Fucose, Chondrotin Disaccharide co-treatment. Alkaline Phosphatase activity levels significantly increased following co-treatment with F-Fucose, Chondroitin Disaccharide and co-treatments with F-Fucose, Chondroitin Disaccharide. A statistically significant increase was detected at all concentrations. The largest increase was elicited by 0.1% w/v F-fucose + 0.001% w/v CS (+192%) and 0.01% w/v F-fucose + 0.0001% w/v CS (+171%) at 168 hours post treatment.
  • Figure 7 Percentage change in levels of Collagen and Elastin protein production, % versus control untreated cell at l20hrs post treatment with chondroitin disaccharide Adi-4S sodium salt across a range of concentrations (0.01%; 0.001%; 0.0001% w/v). Production levels were normalised against control buffer only unrelated cells. * p ⁇ 0.05; ** p ⁇ 0.01; *** p ⁇
  • Figure 8 Effect of co-treatment of Chondroitin Sulphate Disaccharide and F-Fucose on collagen and elastin protein production levels % versus control untreated cells at 120 hrs post treatment. Production levels were normalised against control buffer only unrelated cells. * p ⁇ 0.05; ** p ⁇ 0.01; *** p ⁇ 0.001; **** p ⁇ 0.0001
  • “comprising,” are to be read to indicate the inclusion of any recited integer (e.g. a feature, element, characteristic, property, method/process step or limitation) or group of integers (e.g. features, element, characteristics, properties, method/process steps or limitations) but not the exclusion of any other integer or group of integers.
  • a recited integer e.g. a feature, element, characteristic, property, method/process step or limitation
  • group of integers e.g. features, element, characteristics, properties, method/process steps or limitations
  • the term“disease” is used to define any abnormal condition that impairs physiological function and is associated with specific symptoms.
  • the term is used broadly to encompass any disorder, illness, abnormality, pathology, sickness, condition or syndrome in which physiological function is impaired irrespective of the nature of the aetiology (or indeed whether the aetiological basis for the disease is established). It therefore
  • treatment refers to an intervention (e.g. the administration of an agent to a subject) which cures, ameliorates or lessens the symptoms of a disease or removes (or lessens the impact of) its cause(s) (for example, the reduction in accumulation of pathological levels of lysosomal enzymes).
  • the term is used synonymously with the term“therapy”.
  • treatment refers to an intervention (e.g. the administration of an agent to a subject) which prevents or delays the onset or progression of a disease or reduces (or eradicates) its incidence within a treated population.
  • the term treatment is used synonymously with the term “prophylaxis”.
  • the term“treatment” generally refers a treatment that results in one or more of improvement in hair growth (increasing the rate of growth, or density of growth, or both), or slowing or inhibiting hair loss, or improving the condition of hair, including , composition and/or quality of hair.
  • the term“treatment” can be a cosmetic treatment, where the skin is normal (i.e. skin anti-aging, or skin rejuvenation), or a therapeutic treatment, where the skin is not normal (skin condition such as dermatitis or excema).
  • an effective amount or a therapeutically effective amount as applied to the active agents means amounts which effect an increase in hair growth, an improvement of hair condition, including composition and/or quality of hair, or decrease in hair loss, or amounts which effect an increase collagen or elastin production.
  • effective amount means 5.0 to 0.005 % L-fucose (w/v) and 1.0 to 0.00001 % chondroitin disaccharide (w/v).
  • effective amount means 1.0 to 0.005 % L-fucose (w/v) and 0.1 to 0.00001 % chondroitin disaccharide (w/v).
  • the effective amounts of L-fusose and chondroitin disaccharide may be increased for oral formulations compared with topical formulations.
  • the term subject (which is to be read to include “individual”, “animal”, “patient” or “mammal” where context permits) defines any subject, particularly a mammalian subject, for whom treatment is indicated.
  • Mammalian subjects include, but are not limited to, humans, domestic animals, farm animals, zoo animals, sport animals, pet animals such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, cows; primates such as apes, monkeys, orangutans, and chimpanzees; canids such as dogs and wolves; felids such as cats, lions, and tigers; equids such as horses, donkeys, and zebras; food animals such as cows, pigs, and sheep; ungulates such as deer and giraffes; and rodents such as mice, rats, hamsters and guinea pigs.
  • the subject is a human.
  • condition characterised by excessive hair loss of impaired hair growth refers to a medical condition that manifests in excessive hair loss or impaired hair growth.
  • conditions include alopecia, traction alopecia, alopecia areata, androgenetic or androgenic alopecia, tinea capitis, telogen effluvium, scalp infections, diseases that cause scarring alopecia, hair pulling disorders, and conditions associated with hormonal disorders such as pregnancy, childbirth, menopause.
  • the term“disorder of the skin” as applied to a mammal, especially a human refers to a disease or condition characterised by damaged dermal or epithelial tissue.
  • the disorder may be an inflammatory disorder of the skin, for example dermatitis, psoriasis or eczema, or it may be a condition having a microbial basis, for example a skin infection.
  • topical composition refers to a composition that is formulated for topical administration.
  • Topical administration refers to the application to the keratinous tissue, such as the hair and areas of the skin where hair grows, or to the skin.
  • formulations for topical delivery are described in Topical drug delivery formulations edited by David Osborne and Antonio Aman, Taylor & Francis, the complete contents of which are incorporated herein by reference.
  • An alternative means of topical administration is transdermal administration, for example by use of a skin patch.
  • the active ingredient can be incorporated into a cream consisting of an aqueous emulsion of polyethylene glycols or liquid paraffin.
  • Compositions may be formulated in unit dosage form, i.e., in the form of discrete portions containing a unit dose, or a multiple or sub-unit of a unit dose.
  • the term“cosmetic composition” when used herein relates to a composition that can be used for cosmetic purposes, personal care and/or hygiene purposes. It will be appreciated that the composition may have more than one cosmetic purpose and may be used for more than one of these purposes at the same time.
  • the cosmetic composition may be in the form of a hair treatment composition such as a shampoo or conditioner.
  • a “cosmetic” when used herein can include but are not limited to, lipstick, mascara, rouge, foundation, blush, eyeliner, facial and body powder, sunscreen, sunblock, nail polish, compacts, solids, pencils.
  • composition formulated for oral administration means a composition that is suitable for ingestion by a mammal.
  • the composition may be a pharmaceutical composition and include one or more
  • composition is provided in the form of a unit dose product, and may be in the form of a tablet, capsule, pill, ampoule, sachet, or any other unit dose form.
  • chondroitin disaccharide refers to a disaccharide unit composed of glucuronic (GlcA) and N-acetylgalactosamine (GalNAc), or a cosmetically
  • This disaccharide is the sub-unit of the polymer Chondroitin (Pubmed CID 53477707) from which it is generally derived).
  • Proteoglycans containing chondroitin sulphate are ubiquitous in nature and can be found in connective tissue matrix, cell surface and basement membranes, intracellular granules of certain cells, plant tissue and seaweeds.
  • Chondroitin disaccharide may be provided as a free base or a salt.
  • examples of specific chondroitin disaccharides include chondroitin disaccharide Adi-4S sodium salt (Sigma Aldrich); chondroitin disaccharide Adi-US-2S sodium salt (Sigma Aldrich); chondroitin disaccharide 5di-6S sodium salt (Santa Cruz Biotechnology); chondroitin disaccharide 5di- 4S sodium salt (Creative-Enzymes); chondroitin disaccharide di-OS sodium salt
  • the chondroitin disaccharide is derived from a natural source from plant or animal, marine or terrestrial sources. In one embodiment, the chondroitin disaccharide is derived from a marine algae source. . Examples of chondroitin disaccharidesinclude chondroitin disaccharide Adi-4S sodium salt (Sigma Aldrich), and chondroitin disaccharide Adi-US-2S sodium salt (Sigma Aldrich). Chondroitin
  • disaccharides may be obtained from commercial sources (as described above), or may be extracted from natural products by extracting chondroitin sulphate from the natural source using CS digesting enzymes (for example a CS digesting enzyme derived from
  • the term“L-fucose” refers to a hexose deoxy sugar that exists in nature in the L-configuration (and which lacks a hydroxyl group on the carbon at the six position - hence deoxy) or a cosmetically pharmaceutically acceptable salt thereof. It is found in nature on N-linked glycans in a wide variety of organisms, including mammal, insect and plant cell surfaces.
  • the L-fucose is derived from a natural source.
  • the L-fucose is derived from a marine algae source, preferably seaweed.
  • L-fucose derived from seaweed examples include L-(-)-Fucose (Sigma Aldrich - F2252). L-fucose is described in the following articles: Becket et al. (Glycobiology 2003 13(7); Ale et al. (Marine Drugs 2011 (Nov)); and Gerber et al (The New Phytrologist 2014 (June). Fucose can be released from fucose containing polymers by an enzyme called a- fucosidase. L-Fucose may also be produced via biotechnological processes or via extraction from other plant, fruit, vegetable and fungi species such as mushrooms, tomatoes, brewers yeast and various seeds. As used herein, the term“actives” refers to chondroitin disaccharide and L-fucose.
  • cosmetically or pharmaceutically acceptable salt means a salt recognized for its use in animals and more specifically in human beings, and includes salts used to form base addition salts, either they are inorganic, such as and not restricted to, lithium, sodium, potassium, calcium, magnesium, manganese, copper, zinc or aluminium among others, either they are organic, such as and not restricted to, ethylamine, diethylamine,
  • ethylenediamine, ethanolamine, diethanolamine, arginine, lysine, histidine or piperazine among others, or acid addition salts either they are organic, such as and not restricted to, acetate, citrate, lactate, malonate, maleate, tartrate, fumarate, benzoate, aspartate, glutamate, succinate, oleate, trifluoroacetate, oxalate, pamoate or gluconate among others, or inorganic, such as and not restricted to, chloride, sulfate, borate or carbonate, among others.
  • the nature of the salt is not critical, provided that it is cosmetically or pharmaceutically acceptable.
  • the cosmetically or pharmaceutically acceptable salts of the actives of the invention can be obtained by the conventional methods, well known in the prior art.
  • the topical composition of the invention may be presented in a formulation selected from the group comprising creams, multiple emulsions, anhydrous compositions, aqueous dispersions, oils, milks, balsams, foams, lotions, gels, cream gels, hydro-alcoholic solutions, hydro-glycolic solutions, cosmetic, personal care product, hydrogels, liniments, sera, soaps, dusting powder, paste, semi solid formulations, liniments, serums, shampoo, conditioner, ointments, any rinse off formulation, talc, mousses, powders, sprays, aerosols, solutions, suspensions, emulsions, syrups, elixirs, polysaccharide films, patches, gel patches, bandages, an adhesive system, water-in-oil emulsions, oil-in-water emulsions, and silicone emulsions.
  • the emulsion contains a lipid or oil.
  • the emulsion may be, but is not limited to, oil-in-water, water-in-oil, water-in-oil-in-water and oil-in-water-in-silcone emulsions.
  • the emulsion may contain a humectant.
  • the emulsion may contain an anti- foaming agent, such as silicone.
  • the emulsion may have any suitable viscosity.
  • Emulsions may further contain an emulsifier and/or an anti-foaming agent.
  • the topical composition of the invention may be incorporated into a medical device for administration.
  • a medical device for administration.
  • a device can include but is not limited to a fabric, patch, bandage, gauge, sock, tight, underwear, dressing, glove, mask, adhesive patches, non-adhesive patches, occlusive patches and microelectric patches or suitable adhesive system.
  • the device is in direct contact with the keratinous layer such as the skin, thus releasing the actives of the invention.
  • the topical composition may be incorporated in any suitable form as detailed herein.
  • the topical composition of the invention can be incorporated into the device or be present on the surface of the device or can be in a cream, gel or wax formulation or any suitable formulation defined herein and incorporated into the device or on the surface of the device.
  • the device may be adapted for adhesion or attachment to the skin from which hair is growing.
  • the device is adapted to release a constant quantity of the composition of the invention. It will be understood that the amount of the composition contained in the sustained release system will depend, for example, on where the composition is to be administered, the kinetics and duration of the release of the composition of the invention, as well as the nature of the condition, disorder and/or disease to be treated and/or cared for.
  • the device may be such that the composition is released by biodegradation of the device, or by friction between the device and the body, due to bodily moisture, the skin's pH or body temperature.
  • the topical composition may further comprise at least one cosmetically acceptable excipient.
  • Excipient may be used interchangeably with functional ingredient or additive. It will be understood that although the topical
  • compositions of the current invention can be administered alone, they will generally be administered in admixture with a cosmetic excipient.
  • Cosmetically acceptable excipients are well known in the art and any known excipient, may be used provided that it is suitable for topical administration and is dermatologically acceptable without undue toxicity, incompatibility and/or allergic reaction.
  • the amount of excipient included will depend on numerous factors, including the type of excipient used, the nature of the excipient, the component(s) of the topical composition, the amount of active in the topical composition and/or the intended use of the topical composition. The nature and amount of any excipient should not unacceptably alter the benefits of the actives of this invention.
  • the excipient may be a suitable diluent, carrier, binder, lubricant, suspending agent, coating agent, preservative, stabilisers, dyes, vehicle, solubilising agent, base, emollient, emulsifying agent, fragrance, humectant, and/or surfactants.
  • suitable diluents include, but are not limited to, any diluent disclosed in disclosed in US2014120131 or US2004132667. Examples include ethanol, glycerol and water.
  • suitable carriers include, but are not limited to, lactose, starch, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol and any suitable carrier disclosed in US2014120131 or US2004132667.
  • suitable binders include, but are not limited to, starch, gelatin, glycerine, natural sugars such as glucose, anhydrous lactose, free- flow lactose, beta-lactose, com sweeteners, natural and synthetic gums, such as acacia, tragacanth or sodium alginate, carboxymethyl cellulose and polyethylene glycol and any suitable binder disclosed in US2014120131 or US2004132667.
  • Suitable lubricants include, but are not limited to, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, and sodium chloride and any suitable lubricant disclosed in US2014120131 or US2004132667.
  • the carrier may be any suitable carried known in the art or disclosed in US2014120131 or US2004132667.
  • the carrier may include, but is not limited to, a liquid, such as water, oils or surfactants, including those of petroleum, animal, plant or synthetic origin, polymer, oil, such as peanut oil, mineral oil, castor oil, soybean oil, alcohol, polysorbates, sorbitan esters, ether sulfates, sulfates, betaines, glycosides, maltosides, fatty alcohols, nonoxynols, poloxamers, polyoxyethylenes, polyethylene glycols, dextrose, glycerol, or digitonin. It will be understood that the carrier will be dermatologically acceptable.
  • Preferred carriers contain an emulsion such as oil-in-water, water-in-oil, water- in-oil- in- water and oil- in-water- in- silicone emulsions. Emulsions may further contain an emulsifier and/or an anti-foaming agent.
  • the topical composition may further comprise one or more additional ingredients.
  • the topical composition of the invention may be administered consecutively, simultaneously or sequentially with the one or more other additional agents.
  • additional ingredients may be those of benefit to include in a topical composition, or of benefit depending on the intended use of the topical composition.
  • the additional ingredient may be active or functional or both.
  • additional ingredients include, but are not limited to, one or more of cleaning agents, conditioning agents, sunscreen, pigment, moisturiser, thickening agents, gelling agents, essential oil, astringents, pigments, anti-caking agent, anti-foaming agent, binders, additives, buffers, chelating agents, external analgesics, film formers or materials, bulking agents, polymers, opacifying agents, pH adjusters, propellants, reducing agents, sequestrants, skin bleaching and lightening agents, skin conditioning agents, aloe vera, healing agents, soothing agents, smoothing agents, pantothenic acid, treating agents, thickeners, vitamins colourants, pharmaceuticals, antiseptic agents, antifoaming agents, buffering agents, astringents, polymers, pH adjuster, deodorant or any other
  • dermatologically acceptable carrier or surfactant is dermatologically acceptable.
  • the topical composition may be alcohol free.
  • the composition further comprises one or more additional active agents, in addition to the actives of the composition.
  • the composition may be administered with one or more other additional active agents. Typical said additional active agent is present in trace amounts only. In some embodiments, there may be no additional active agent present in the composition.
  • the amount of additional active agent included will depend on numerous factors, including the type of additional active agent used, the nature of the additional active agent, the component(s) of the topical composition, the amount of active in the topical composition and/or the intended use of the topical composition. The nature and amount of any additional active agent should not unacceptably alter the benefits of the actives of this invention.
  • an ingredient that is considered to be an“active” ingredient in one product may be a“functional” or“excipient” ingredient in another and vice versa. It will also be appreciated that some ingredients play a dual role as both an active ingredient and as a functional or excipient ingredient.
  • the additional active agents include glucose transport promoting drugs, skin supplement, agent for treatment and/or care of the skin, anti-inflammatory agent, an anti-aging agent, a cellular growth promoting agent and pharmacological enhancers. Such agents are well known in the art and it will be appreciated that any suitable additional active agent may be used.
  • Additional active agents for treatment and/or care of the skin may include collagen synthesis agents, retinoids, exfoliating agents, anti-cellulite agents, elastase inhibiting agents, melanin synthesis stimulating or inhibiting agents, self-tanning agents, antiaging agents, antimicrobial agents, antifungal agents, fungistatic agents, bactericidal agents, and healing agents. Active agents also include anti inflammatory agents. Any additional active agent should be suitable for application to the skin without undue toxicity, incompatibility and/or allergic reaction. It will be understood that the classification given herein is for clarity and convenience only and not intended to limit the additional ingredient, excipient, or active to that particular application or category listed.
  • the methods and uses of the invention involve administration of a composition of the invention in combination with one or more other active agents, for example, existing growth promoting drugs or pharmacological enhancers available on the market.
  • the compounds of the invention may be administered consecutively, simultaneously or sequentially with the one or more other active agents.
  • the topical composition of the invention is administered in a cosmetically or
  • compositions of the invention in an amount that is non-toxic but sufficient amount to provide the desired effect such as improved hair growth, inhibited hair loss, or improvement of hair condition. It will be appreciated that a person skilled in the art would be capable of determining an appropriate dose of the topical compositions of the invention to administer without undue experimentation. Alternatively, a physician will determine the actual dose that is most suitable for a patient depending on the particular condition, disease or disorder to be treated or cared for and the age, body weight and/or health of the person.
  • administration can vary greatly, depending on the needs of each subject, with a
  • recommendation of an application or administration range from once a month to ten times a day, preferably from once a week to four times a day, more preferably from three times a week to three times a day, even more preferably once or twice a day.
  • the topical composition may be applied by, but not limited to, rubbing, or massaging into the hair or skin where hair grows to be treated or cared for.
  • the composition is left on or not removed from the area of the body.
  • the composition of the invention may be applied to an area to be treated by means to achieve a greater penetration of the composition of the invention, such as, but not limited to, iontophoresis, sonophoresis, electroporation, microelectric patches, mechanical pressure, osmotic pressure gradient, occlusive cure, micro injections or needle- free injections by means of pressure, such as injections by oxygen pressure, or any combination thereof.
  • the composition may be delivered via any one of liposomes, mixed liposomes, oleosomes, niosomes, ethosomes, millicapsules, capsules, macrocapsules, nanocapsules, nanostructured lipid carriers, sponges, cyclodextrins, vesicles, micelles, mixed micelles of surfactants, surfactant-phospholipid mixed micelles, millispheres, spheres, lipospheres, particles, nanospheres, nanoparticles, milliparticles, solid nanopartciles as well as microemulsions including water-in-oil microemulsions with an internal structure of reverse micelle and nanoemulsions microspheres, microparticles.
  • the delivery system may be a sustained release system wherein the composition of the invention is gradually released during a period of time and preferably with a constant release rate over a period of time.
  • the delivery systems are prepared by methods known in the art. The amount of active contained in the sustained release system will depend on where the composition is to be delivered and the duration of the release as well as the type of the condition, disease and/or disorder to be treated or cared for.
  • the topical composition of the invention may be for human or animal usage in human and veterinary medicine.
  • the term“personal care product” should be understood to mean a composition formulated for use by humans in cleaning or treating the human body, particularly the skin and hair.
  • Examples include shampoo, conditioner, skin creams and lotions, powders, dentifrice, shower gel or creams, bath or shower gel, hair dye, soap, body scrub, exfoliant, anti-dandruff solutions body lotion, moisturisers, cleaners, masks, oils, serums, and rinses.
  • the term “dermatologically acceptable,” means that the topical
  • composition(s) or component(s) of the composition(s) are suitable for use in contact with human skin without risk of toxicity, incompatibility, instability and/or allergic response, and similar.
  • compositions of the invention e.g., encapsulation in liposomes, microparticles, microcapsules.
  • Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes.
  • the compounds or compositions may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local.
  • Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.
  • the compounds can be delivered in a vesicle, in particular a liposome (see Langer, Science, 1990, 249, 1527-1533; Treat et ah, in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353- 365 (1989); Lopez-Berestein, ibid., pp. 317-327).
  • a liposome see Langer, Science, 1990, 249, 1527-1533; Treat et ah, in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353- 365 (1989); Lopez-Berestein, ibid., pp. 317-327).
  • the compounds or compositions of the invention can be delivered in a controlled release system.
  • a pump may be used (see Langer, supra; Sefton, CRC Crit. Ref. Biomed. Eng., 1987, 14, 201; Buchwald et ah, Surgery, 1980, 88, 75; Saudek et ah, N. Engl. J. Med., 1989, 321, 574).
  • polymeric materials can be used (see Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Press., Boca Raton, Fla.
  • a controlled release system can be placed in proximity of the therapeutic target, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984)). Other controlled release systems are discussed in the review by Langer (Science, 1990, 249, 1527-1533).
  • compositions comprise an effective amount of L-fucose and chondroitin disaccharide, and a
  • pharmaceutically acceptable excipient or carrier means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals and more particularly in humans.
  • excipient refers to a diluent, adjuvant, excipient, or vehicle with which the compound or pro-drug of the invention is administered.
  • Such pharmaceutical excipients can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
  • Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene glycol and water.
  • EXAMPLE 1 Effect of L-fucose and chondroitin disaccharide on DPC proliferation.
  • Dermal Papilla Cells were seeded at a density of 10,000 cells per well in 96-well plates in 100 m ⁇ of complete media. Cells were allowed to adhere overnight.
  • Treatment media was prepared containing appropriate concentration of L-fucose
  • Treatment media was prepared containing appropriate concentration of chondroitin disaccharide D di-4S sodium salt:
  • Treatment media was prepared containing appropriate concentration of L-fucose and chondroitin disaccharide D di-4S sodium salt:
  • Treatments were performed in triplicate wells. Cells were cultured for a further 24, 48 and 72 hours. No media changes were performed between initial treatment and cell assays. Media only was used to treat controls cells. An additional control was used to assess the impact of solvent (H 2 0 Control). After exposure for the desired period of time 11 m ⁇ PrestoBlue reagent was added to each well of the 96-well plate. Plates were incubated in the dark for 2 hrs at 37°C. Fluorescence was read using a 560 nm excitation/590 nm emission filter set (lOnm bandwidth). Fluorescence data in wells containing cells were corrected for background fluorescence using cell free media control replicates.
  • pNPP p-nitrophenyl phosphate
  • Treatment media was prepared containing appropriate concentration of 1) L-fucose, 2) chondroitin disaccharide and 3) L-fucose + chondroitin disaccharide D di-4S sodium salt as described above:
  • lysis buffer was added to each well.
  • Cells were transferred into eppendorf tubes and subjected to 3 freeze thaws to ensure cells lysis. Cell suspensions were centrifuged at 2500g for 10 min at 4°C. Supernatants were used to AP assay.
  • a 2-fold serial dilution of calf AP standard was resulting in concentrations of 100, 50, 25, 12.5, 6.2, 3.1, and 0 ng/ml AP solutions.
  • 50 m ⁇ of each standard dilution and each lysate sample was added in triplicate to a 96-well plate.
  • 50 m ⁇ of pNPP substrate solution was added and the reagents were mixed by gently shaking
  • EXAMPLE 3 L-fucose and chondroitin disaccharide effect on Dermal Papilla Cells proliferation.
  • results are expressed as a percentage of control from three independent experiments. Statistical significance of the differences in mean values was assessed using one-way ANOVA followed by Dunnett's multiple comparison test.
  • Alkaline Phosphatase activity levels were evaluated at 72, 120 & 168 hours post treatment. A statistically significant increase in Alkaline Phosphatase production in response to all used concentrations at all-time points.
  • Figure. 3 and Table 2 from (38 - 43%) at 72 hours post treatment further increasing in a concentration dependent manner, with the largest increase of 128% in response to 0.01% w/v at 168 hours post treatment.
  • results are expressed as a percentage of control from three independent experiments. Statistical significance of the differences in mean values was assessed using one-way ANOVA followed by Dunnett's multiple comparison test.
  • Table 2 Alkaline Phosphatase Activity Levels in dermal papilla cells in response to L- Fucose, Chondroitin Disaccharide co -treatments. Alkaline Phosphatase activity levels significantly increased following treatment with L-Fucose, Chondroitin Disaccharide and co-treatments with L-Fucose & Chondroitin Disaccharide. A statistically significant increase was detected at all concentrations. The largest increase was elicited by 0.1% w/v L- fucose + 0.001% w/v CS and 0.01% w/v L-fucose + 0.0001% w/v CS at 168 hours post treatment. Data on treating cells with only L-Fucose or Chondroitin Disaccharide is included for comparison.
  • Figure 5 shows that dermal Cell Proliferation rates significantly increase following treatment with Chondroitin Sulphate Disaccharide (% change) at 24 & 48 hours post treatment, and that the increase is greater compared with treatment with L-fucose.
  • Human Dermal Fibroblast Cells were seeded at a density of 10,000 cells per well in 6-well plates in 100 m ⁇ of complete media. Cells were allowed to adhere overnight.
  • Treatment media was prepared containing appropriate concentration of chondroitin disaccharide D di-4S sodium salt:
  • Treatments were performed in triplicate wells. Cells were cultured for a further 24, 48 and 72 hours. No media changes were performed between initial treatment and cell assays. Media only was used to treat controls cells. An additional control was used to assess the impact of solvent (H 2 0 Control). After exposure for the desired period of time 11 m ⁇ PrestoBlue reagent was added to each well of the 96-well plate. Plates were incubated in the dark for 2 hrs at 37°C. Fluorescence was read using a 560 nm excitation/590 nm emission filter set (lOnm bandwidth). Fluorescence data in wells containing cells were corrected for background fluorescence using cell free media control replicates.
  • Figure 6 shows that dermal fibroblast cell proliferation rates increase following treatment with L-Fucose. (% change) at 24 & 48 hours post treatment. Proliferation levels were normalised against control buffer only unrelated cells. * p ⁇ 0.05; ** p ⁇ 0.01; *** p ⁇
  • Treatment media was prepared containing appropriate concentration of L-fucose
  • Treatments were performed in triplicate wells. Cells were cultured for a further 24, 48 and 72 hours. No media changes were performed between initial treatment and cell assays. Media only was used to treat controls cells. An additional control was used to assess the impact of solvent (H 2 0 Control). After exposure for the desired period of time 11 m ⁇ PrestoBlue reagent was added to each well of the 96-well plate. Plates were incubated in the dark for 2 hrs at 37°C. Fluorescence was read using a 560 nm excitation/590 nm emission filter set (lOnm bandwidth). Fluorescence data in wells containing cells were corrected for background fluorescence using cell free media control replicates.
  • Figure 7 shows that treatment of dermal fibroblasts with chondroitin disaccharide Adi-4S sodium salt across a range of concentrations (0.01%; 0.001%; 0.0001% w/v) causes a significant percentage change in levels of Collagen and Elastin protein production, % versus control untreated cell at l20hrs post treatment. Production levels were normalised against control buffer only unrelated cells. * p ⁇ 0.05; ** p ⁇ 0.01; *** p ⁇ 0.001; **** p ⁇ 0.0001
  • Human Dermal Fibroblast Cells were seeded at a density of 2x10 4 cells per well in 6-well plates in 400 m ⁇ of complete media. Cells were allowed to adhere overnight. Treatment media was prepared containing appropriate concentration of chondroitin disaccharide D di- 4S sodium salt:
  • Capture Antibody was diluted to working concentration in PBS without carrier protein. Wells were immediately coated with 100 m ⁇ of the diluted Capture Antibody, plated sealed and incubated overnight at room temperature. Each well was aspirated, 400ul of wash Buffer was added per well, and aspirated, this was repeated 3 x.
  • Figure 8 shows that co-treatment of dermal fibroblast cells with Chondroitin Sulphate Disaccharide and L-Fucose causes a significant increase in collagen and elastin protein production levels % versus control untreated cells at 120 hrs post treatment.
  • Human Dermal Fibroblast Cells were seeded at a density of 2x10 4 cells per well in 6-well plates in 400 m ⁇ of complete media. Cells were allowed to adhere overnight. Treatment media was prepared containing appropriate concentration of chondroitin disaccharide D di- 4S sodium salt:
  • Treatment media was prepared containing appropriate concentration of F-fucose and chondroitin disaccharide D di-4S sodium salt:
  • Table 3 demonstrates the effect of combinations of Chondroitin Sulphate Disaccharide and L-Fucose on collagen and elastin protein production levels at 120 hrs post treatment, highlighting the synergistic effects elastin or elastin production of the co-treatments versus treatment with Chondroitin Sulphate Disaccharide and L-Fucose alone at same
  • the composition is formulated for topical application as defined herein.
  • the composition is an emulsion or cream or a rub.
  • the cream comprises an excipient or diluent, a suspending agent, a preservative and an effective amount of chondroitin disaccharide and L-fucose.
  • the cream comprises an alcohol, a carbomer, a sorbate, water, and an effective amount of chondroitin sulphate and L-fucose.
  • the alcohol is butylene glycol (l,3-butanediol).
  • the alcohol may be present in an amount of between 1 and 10 % of the composition, preferably between 2 and 6%, preferably 4%.
  • the sorbate may be polysorbate-20.
  • the sorbate may be present in an amount of between .01 to 1% of the composition, preferably between .05 and .5%, preferably 0.10%. Water is present in an amount of between 10% and 90%, preferably 30% to 75%.
  • the carbomer may be present in an amount of from 0.05% to 1%, preferably, 0.1% to 0.5%, preferably, 0.15%.
  • the carbomer may be Ultrez 10.
  • the actives may be included in an amount of 1.0 to 0.005 % L-fucose (w/v) and 0.1 to 0.00001 % chondroitin disaccharide (w/v).
  • the composition may further comprise one or more of sugar alcohol such as glycerine, parabens, silicon, such as cyclohexasiloxane, a fatty alcohol or phosphoric acid or a mixture of fatty alcohol and phosphoric acid, such as cetearyl alcohol, dicetyl phosphate and Cereth 10 phosphate or combinations thereof, a polyoxyethylene stearyl ethers, such as Steareth 2 and 10, and a fragrance.
  • sugar alcohol such as glycerine, parabens, silicon, such as cyclohexasiloxane, a fatty alcohol or phosphoric acid or a mixture of fatty alcohol and phosphoric acid, such as cetearyl alcohol, dicetyl phosphate and Cereth 10 phosphate or combinations thereof
  • a polyoxyethylene stearyl ethers such as Steareth 2 and 10
  • the resulting emulsion is suited as a rub.
  • the rub is suitable for fragile aged skin.
  • the emulsion is suitable for improving hair growth and condition, and inhibiting hair loss.
  • the emulsion is prepared in the following way: Phase A: disperse Ultrez 10 (carbomer) in water and let is swell for 20 minutes, then add phase B; heat to 75°C. Heat Phase C separately to 75°C. Mix the two phases under stirring, homogenise, add Phase D, neutralise with Phase E, cool until reaching 30°C, then add Phase F and Phase G; adjust to pH to 6 with ⁇ NaOH. It will be understood that this is an example only and any suitable method known in the art may be used.
  • the composition may comprise one or more of water, a carbomer, a sorbate such as potassium sorbate, a sugar alcohol, such as glycerine, an alcohol such as 2- (2-Ethoxyethoxy)ethanol, a polyoxyethylene stearyl ethers, such as Steareth 2, a fatty alcohol or phosphoric acid or a mixture of fatty alcohol and phosphoric acid , such as cetearyl alcohol, dicetyl phosphate and Cereth 10 phosphate or combinations thereof, a siloxane, such as cyclomethicone, a Caprylic Capric Triglycerides, a sorbitan Stearate, Parabens, Sodium hydroxide, chondroitin disaccharide and L-fucose.
  • a sugar alcohol such as glycerine
  • an alcohol such as 2- (2-Ethoxyethoxy)ethanol
  • a polyoxyethylene stearyl ethers such as Steareth 2
  • Example 11 The following composition in Example 11 is an example of an emulsion or cream or a rub.
  • This formulation can be made according to the procedures generally outlined in Example 1.
  • the composition may be an emulsion or cream or rub comprising one or more of water, a carbomer, such as Ultrez 10, a sugar alcohol, such as glycerine, an alcohol such as phenova (phenoxy ethanol and mixed parabens), a fatty acid ester such as ethylhexyl palmitate, a fatty alcohol such as cetearyl alcohol, a lactic acid ester such as myristyl lactate, a sorbate such as polysorbate 20 and/or potassium sorbate, a polymeric emulsifier such as Acrylate (C10-30 alkyl acrylate) and a cross polymer, a siloxane, such as cyclomethicone, sodium hydroxide, and the active agents
  • a carbomer such as Ultrez 10
  • a sugar alcohol such as glycerine
  • an alcohol such as phenova (phenoxy ethanol and mixed parabens)
  • a fatty acid ester such as ethy
  • This emulsion or rub is prepared in the following way: Phase A disperse Ultrez 10 (carbomer) in water and let it swell for 20 minutes, then add phase B; heat to 75°C. Heat Phase C separately to 75°C. Mix the two phases under stirring, homogenise, add Phase D, neutralise with Phase E, cool until reaching 30°C., then add Phase F and Phase G, adjust pH to -6 with NaOH.
  • the composition may be an emulsion, cream or a gel, preferably a gel, comprising one or more of water, a carbomer, such as Ultrez 10, a sugar alcohol, such as glycerine, an alcohol such as phenova (phenoxy ethanol and mixed parabens), a sorbate such as polysorbate 20 and/or potassium sorbate, a polymeric emulsifier such as Acrylate (Ci 0-30 alkyl acrylate), a siloxane, such as cyclomethicone, sodium hydroxide, an active agent and optionally a suitable moisturising agent, such as an agent comprising Imperata cylindrica (root) extract, water, glycerine, PEG-8, and carbomer (MOIST 24).
  • the gel is a moisturising gel.
  • the following composition in Example 13 is an example of a gel.
  • the gel is a moisturising gel.
  • This formulation can be made according to the procedures generally outlined in Example 3.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition destinée à traiter les cheveux pour améliorer l'état, la qualité ou la composition des cheveux, ou destinée à traiter la peau pour la rajeunir ou pour réduire l'aspect de vieillissement de la peau, ou pour améliorer l'aspect de la peau. La composition comprend des quantités efficaces de L-fucose et de disaccharide de chondroïtine. Elle est formulée en vue d'une application topique sur les cheveux, sur la peau sur laquelle les cheveux poussent, ou sur la peau, ou formulée en vue d'une administration orale.
PCT/EP2019/056511 2018-03-16 2019-03-14 Composition de traitement WO2019175364A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB1804226.7A GB2572322A (en) 2018-03-16 2018-03-16 A hair treatment composition
GBGB1804251.5A GB201804251D0 (en) 2018-03-16 2018-03-16 A skin treatment composition
GB1804226.7 2018-03-16
GB1804251.5 2018-03-16

Publications (1)

Publication Number Publication Date
WO2019175364A1 true WO2019175364A1 (fr) 2019-09-19

Family

ID=66182478

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/056511 WO2019175364A1 (fr) 2018-03-16 2019-03-14 Composition de traitement

Country Status (1)

Country Link
WO (1) WO2019175364A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006016313A (ja) * 2004-06-30 2006-01-19 Toshie Tsuchiya ギャップ機能抑制剤、細胞増殖促進剤及び硫酸化ポリフコース
JP2015178493A (ja) * 2014-02-28 2015-10-08 マルホ株式会社 トロポエラスチン発現促進剤およびエラスチン産生促進剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006016313A (ja) * 2004-06-30 2006-01-19 Toshie Tsuchiya ギャップ機能抑制剤、細胞増殖促進剤及び硫酸化ポリフコース
JP2015178493A (ja) * 2014-02-28 2015-10-08 マルホ株式会社 トロポエラスチン発現促進剤およびエラスチン産生促進剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE GNPD [online] MINTEL; 21 January 2015 (2015-01-21), ANONYMOUS: "Total Repair Serum", XP055599355, retrieved from www.gnpd.com Database accession no. 2876237 *

Similar Documents

Publication Publication Date Title
EP1600143B1 (fr) PRÉPARATION DERMIQUE À USAGE EXTERNE CONTENANT UN SUCRE DÉRIVÉ DE LA a,a-TRÉHALOSE
KR20190037229A (ko) 상승효과적 항진균 조성물 및 그의 방법
KR101018352B1 (ko) 봉독을 유효성분으로 하는 여드름 예방 및 치료용 조성물
JPWO2004016236A1 (ja) 化粧料
KR101514970B1 (ko) 피토스핑고신-1-포스페이트 또는 그 유도체를 포함하는 아토피 또는 피부상처 치료 또는 예방용 조성물
BRPI0808065B1 (pt) New cosmetic and / or pharmaceutical compositions and their applications
CN109260059B (zh) 一种具有祛痘和皮肤修复功效的精油组合物及应用
JP2005306831A (ja) 皮膚外用剤
CN107822945A (zh) 一种赛天然酵母组合物、制备方法及在化妆品中应用
WO2020006496A1 (fr) Compositions bioactives et procédés de traitement de la peau
US20200000698A1 (en) Bioactive compositions and methods for treating skin
CN102939080A (zh) 利用4-乙酰氧基-白藜芦醇提供增强的白藜芦醇活性的方法
KR20160044360A (ko) 탈모방지 또는 발모개선용 조성물
KR20110056884A (ko) 마그네슘 아스코르빌 포스페이트(ｍａｐ) 및 메틸설포닐메탄(ｍｓｍ) 혼합물을 유효성분으로 함유하는 탈모 방지 및 발모 개선용 조성물
GB2572322A (en) A hair treatment composition
FR2984129A1 (fr) Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des etats pelliculaires du cuir chevelu
WO2015001891A1 (fr) Composition pour augmenter la production de collagène, pour augmenter la production d'élastine et/ou pour activer la migration des kératinocytes et son utilisation
WO2019175364A1 (fr) Composition de traitement
CN115209887A (zh) Ppar激动剂复合物及其使用方法
JP2009234976A (ja) 細胞賦活剤、及び老化防止用皮膚外用剤
JP6089163B1 (ja) 美容組成物
JP4773670B2 (ja) エラスチン様作用剤及びこれを含む化粧料
CN113058026B (zh) Kisspeptin-234在促进毛发生长中的应用
WO2018225728A1 (fr) Promoteur de production de glycosaminoglycane, et composition pour promouvoir la production de glycosaminoglycane
JPH06128141A (ja) 皮膚外用剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19717758

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19717758

Country of ref document: EP

Kind code of ref document: A1